The University of Windsor, in partnership with Shogun Maitake Canada, has unveiled groundbreaking findings that could redefine natural approaches to cancer care across North America. The research, recently highlighted by the university and the company, centres on Odaira Black Maitake Extract (OBME)—a highly concentrated, Health Canada-certified mushroom extract that shows striking anticancer activity.
Dose- and Time-Dependent Cancer Cell Death
Led by Dr. Siyaram Pandey, head of the University of Windsor’s Department of Chemistry and Biochemistry, graduate researchers demonstrated that OBME triggers cancer cell apoptosis—the programmed death of cancerous cells—in a dose- and time-dependent manner. Their in-vitro studies confirmed that higher concentrations and longer treatment durations of OBME markedly reduce cancer cell growth and increase cell death.
In addition to direct cancer cell impact, the team’s data indicate that OBME enhances immune system activity, slows tumour progression, and can augment the effectiveness of conventional chemotherapies. When used alongside standard cancer treatments, OBME may lower toxicity and improve overall quality of life, offering a valuable complement to existing protocols.
Next Phase: Integrating Immunotherapy
The University of Windsor researchers, collaborating with Shogun Maitake Canada, are preparing the next stage of investigation: testing OBME in combination with immunotherapy. This research aims to evaluate whether pairing OBME with advanced immune-based therapies can deliver even stronger clinical outcomes for patients facing various cancers.
A Canadian Hub for High-Quality Maitake Production
Shogun Maitake has operated a state-of-the-art production centre in London, Ontario since 2016, ensuring organic, pesticide-free cultivation of Black Maitake mushrooms. The company’s proprietary methods, perfected by CEO and President Yoshinobu Odaira over four decades, consistently produce mushrooms with superior β-glucan (beta-glucan) content—a key compound linked to immune and anticancer benefits.
Due to the mushroom’s delicate nature, maintaining purity and potency is notoriously challenging. Shogun Maitake’s controlled environment ensures consistent quality that meets or exceeds the standards found in Japan, long known as a global leader in medicinal mushroom production.
From Research to Accessible Supplements
Building on these laboratory results, Shogun Maitake Canada has introduced Shogun Maitake EX, a clinically supported supplement delivering the optimal dosage of OBME. Alongside Prothera, another OBME-based formulation, these products are designed to be taken individually or as a combination care package. Both are registered with Natural Product Numbers (NPNs) from Health Canada—Prothera (NPN: 80115706) and EX (NPN: 80118634)—ensuring regulatory compliance and consumer confidence.
In a mission-led initiative to mark the University of Windsor’s breakthrough, Shogun Maitake will donate 2,000 bottles of its OBME supplements to individuals across North America undergoing cancer treatment. Beginning August 15, 2025, eligible participants can apply at shogunmaitake.com to receive a one-month supply.
Expert Perspective
“These findings offer an incredible opportunity to ease suffering, make chemotherapy more effective, and give cancer patients the immune support to fight back,” said Yoshinobu Odaira. “I have dedicated my life to refining cultivation methods for Black Maitake mushrooms and advancing research that unlocks their full potential in the global fight against cancer.”
A Natural Pathway in Modern Oncology
The University of Windsor–Shogun Maitake collaboration highlights Canada’s growing role in evidence-based natural health innovation. By marrying academic rigour with advanced cultivation technology, the project paves the way for integrative oncology strategies that support patients’ immune systems and reduce treatment side effects.
Health practitioners, natural health retailers, and consumers can follow ongoing developments in OBME research and product availability at shogunmaitake.com. This Canadian-led innovation underscores how functional mushrooms are emerging as powerful allies in next-generation cancer care.
